UNSPSC 51123701: Ambasilide

This classification denotes an antiarrhythmic agent with the molecular formula C21H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 012LYD6KXM, chemically known as 3-(p-aminobenzoyl)-7-benzyl-3,7-diazabicyclo(3.3.1)nonane but more generally known as ambasilide, which bears US NIH Compound Identifier 71270. European Medicines Agency schedules Ambasilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05393MIG.

UNSPSC 51123701 Ambasilide is a Commodity code encompassing advanced life support and emergency medications supplied to state and local health and safety agencies. State and local governments procure these drugs primarily for fire rescue services, emergency medical response, and state pharmacy benefit programs. Recent solicitations show demand for specific injectable formulations — epinephrine, adenosine, labetalol, and diltiazem — supplied with strict expiration-date warranties, rapid delivery cycles (typically within ten days of order), and full replacement liability for expired stock. Issuing bodies range from municipal fire departments to state health agencies operating cooperative purchasing alliances. The City of Tampa's Fire Rescue Department and the Texas Health and Human Services Commission represent the breadth of demand: tactical municipal procurement for immediate operational use alongside strategic state-level initiatives to establish direct relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and wholesaler channels.

The code shows active procurement across at least two states. Tampa, Florida has posted an IFB for advanced life support medications with a response date of April 8, 2026 and an estimated contract value of $40,000.00, designating the award as sheltered for Small Local Business Enterprises with a 5 percent bid discount. Minnesota's multistate cooperative purchasing alliance, MMCAP, administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas RFI issued April 3, 2026 signals emerging procurement interest in direct-to-manufacturer contracting models that bypass traditional intermediaries, representing potential strategic diversification from consolidated wholesaler-dependent supply chains.